| answer text |
<p>Liothyronine is an unbranded generic medicine. The Department encourages competition
between suppliers of unbranded generic medicines to keep prices down. This generally
works well and has led to some of the lowest prices in Europe.</p><p>Concerns about
anti-competitive behaviour are a matter for the Competition and Markets Authority
(CMA) to investigate. Liothyronine, marketed by Concordia, is currently the subject
of an investigation by the CMA, which has provisionally found that Concordia abused
its dominant position to overcharge the National Health Service by millions for liothyronine
tablets. A provisional decision does not necessarily lead to an infringement decision.
Where companies have breached competition law, the Department will seek damages and
invest that money back into the NHS.</p><p>The Department also has its own powers
to limit prices of unbranded generic medicines and will consult early in 2019 with
the relevant industry bodies on implementation of those powers.</p>
|
|
